Respiratory Medicine
Volume 104, Issue 4 , Pages 510-517 , April 2010

Low-dose fluticasone propionate with and without salmeterol in steroid-naïve patients with mild, uncontrolled asthma

  • Paolo M. Renzi

      Affiliations

    • University of Montreal, Montreal, Quebec, Canada
    • ,
  • Lisa A. Howard

      Affiliations

    • GlaxoSmithKline Inc., Mississauga, Ontario, Canada
    • ,
  • Hector G. Ortega

      Affiliations

    • GlaxoSmithKline, Research Triangle Park, NC, USA
    • ,
  • Faiz F. Ahmad

      Affiliations

    • GlaxoSmithKline, Research Triangle Park, NC, USA
    • ,
  • Kenneth R. Chapman

      Affiliations

    • University of Toronto, Toronto, Ontario, Canada
    • Corresponding Author InformationCorresponding author at: Asthma & Airway Centre, University Health Network, Toronto Western Hospital, Room 7-451 East Wing, 399 Bathurst St, Toronto, Ontario, M5T 2S8, Canada. Tel.: +1 416 603 5499; fax: +1 416 603 3456.

Received 16 June 2009 ,Accepted 29 October 2009.

References 

  1. Global Initiative for Asthma (GINA) . Global Strategy for Asthma Management and Prevention. Available from http://www.ginasthma.org2007;
  2. National Heart Lung and Blood Institute . Expert panel report 3: guidelines for the diagnosis and management of asthma. Bethesda, MD: US Department of Health and Human Services; 2007;
  3. Lemiere C, Bai T, Balter M, et al. Adult asthma consensus guidelines update 2003. Can Respir J. 2004;11:9A–18A
  4. Chapman KR, Boulet LP, Rea RM, et al. Suboptimal asthma control: prevalence, detection and consequences in general practice. Eur Respir J. 2008;31:320–325
  5. Fitzgerald JM, Boulet LP, McIvor RA, et al. Asthma control in Canada remains suboptimal: The Reality of Asthma Control (TRAC) study. Can Respir J. 2006;13:253–259
  6. Rabe KF, Vermeire PA, Soriano JB, et al. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J. 2000;16:802–807
  7. Matz J, Emmett A, Rickard K, et al. Addition of salmeterol to low-dose fluticasone versus higher-dose fluticasone: an analysis of asthma exacerbations. J Allergy Clin Immunol 107:783–789.
  8. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ. 2000;320:1368–1373
  9. LaForce CF, Pearlman DS, Ruff ME, et al. Efficacy and safety of dry powder fluticasone propionate in children with persistent asthma. Ann Allergy Asthma Immunol. 2000;85:407–415
  10. Pauwels RA, Löfdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med. 1997;337:1405–1411
  11. Bateman ED, Bousquet J, Keech ML, Busse WW, Clark TJ, Pedersen SE. The correlation between asthma control and health status: the GOAL study. Eur Respir J. 2007;29:56–62
  12. Lundbäck B, Rönmark E, Lindberg A, et al. Control of mild to moderate asthma over 1-year with the combination of salmeterol and fluticasone propionate. Respir Med. 2006;100:2–10
  13. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma controL study. Am J Respir Crit Care Med. 2004;170:836–844
  14. Murray J, Rosenthal R, Somerville L, et al. Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting beta2-agonists. Ann Allergy Asthma Immunol. 2004;93:351–359
  15. Strand AM, Luckow A. Initiation of maintenance treatment of persistent asthma: salmeterol/fluticasone propionate combination treatment is more effective than inhaled steroid alone. Respir Med. 2004;98:1008–1015
  16. Nelson HS, Wolfe JD, Gross G, et al. Efficacy and safety of fluticasone propionate 44μg/salmeterol 21μg administered in a hydrofluoroalkane metered-dose inhaler as an initial asthma maintenance treatment. Ann Allergy Asthma Immunol. 2003;91:263–269
  17. Postma DS, Kerstjens HA, ten Hacken NH. Inhaled corticosteroids and long-acting beta-agonists in adult asthma: a winning combination in all?. Naunyn Schmiedebergs Arch Pharmacol. 2008;378:203–215
  18. Stoloff SW, Stempel DA, Meyer J, et al. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol. 2004;113:245–251
  19. O’Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med. 2001;164:1392–1397
  20. Teeter JG, Bleecker ER. Relationship between airway obstruction and respiratory symptoms in adult asthmatics. Chest. 1998;113:272–277
  21. Zeiger RS, Baker JW, Kaplan MS, Pearlman DS, et al. Variability of symptoms in mild persistent asthma: baseline data from the MIAMI study. Respir Med. 2004;98:898–905
  22. Juniper EF, Wisniewski ME, Cox FM, et al. Relationship between quality of life and clinical status in asthma: a factor analysis. Eur Respir J. 2004;23:287–291
  23. Wolfenden LL, Diette GB, Krishnan JA, et al. Lower physician estimate of underlying asthma severity leads to undertreatment. Arch Intern Med. 2003;163:231–236
  24. Carranza Rosenzweig JR, Edwards L, Lincourt W, et al. The relationship between health-related quality of life, lung function and daily symptoms in patients with persistent asthma. Respir Med. 2004;98:1157–1165
  25. Boulet LP, Phillips R, O’Byrne P, Becker A. Evaluation of asthma control by physicians and patients: comparison with current guidelines. Can Respir J. 2002;9:417–423
  26. Demoly P, Crestani B, Leroyer C, et al. Control and exacerbation of asthma: a survey of more than 3000 French physicians. Allergy. 2004;59:920–926
  27. Miller M, Johnson C, Miller D, et al. Severity assessment in asthma: an evolving concept. J Allergy Clin Immunol. 2005;116:990–995
  28. Vervloet D, Williams AE, Lloyd A, et al. Costs of managing asthma as defined by a derived Asthma Control Test™ score in seven European countries. Eur Respir Rev. 2006;15:17–23
  29. Baumgarten C, Geldszus R, Behre U, et al. Initial treatment of symptomatic mild to moderate bronchial asthma with the salmeterol/fluticasone propionate (50/250microg) combination product (SAS 40023). Eur J Med Res. 2002;7:1–7
  30. Robertson CF, Rubinfeld AR, Bowes G. Pediatric asthma deaths in Victoria: the mild are at risk. Pediatr Pulmonol. 1992;13:95–100
  31. Seung SJ, Mittmann N. Urgent care costs of uncontrolled asthma in Canada. Can Respir J. 2004;2005(12):435–436
  32. Boushey HA, Sorkness CA, King TS, et al. National Heart, Lung, and Blood Institute’s Asthma Clinical Research Network. Daily versus as-needed corticosteroids for mild persistent asthma. N Engl J Med. 2005;352:1519–1528

PII: S0954-6111(09)00360-6

doi: 10.1016/j.rmed.2009.10.025

Respiratory Medicine
Volume 104, Issue 4 , Pages 510-517 , April 2010

Article Tools

* Image Usage & Resolution